Booting Earth Optimization System
Thank you for your patience. Your civilization is very important to us.
Infliximab
Treatment for Interstitial lung disease and pulmonary sarcoidosis
Typical Dosage: 5 mg/kg IV every 4-8 weeks
Effectiveness
60%
Safety Score
35%
Clinical Trials
30
Participants
800
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
35
DangerousModerateSafe
Treatment Details
Dosage Range
5 mg/kg IV every 4-8 weeks
Time to Effect
2-3 months
Treatment Duration
Long-term, potentially indefinite
Evidence Quality
MODERATEConfidence Score
75%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$30,000
Monitoring:$3,000
Side Effect Mgmt:$2,000
Total Annual:$35,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
POORICER
$200,000/QALY
QALYs Gained
0.25
Outcome-Based Costs
Cost per Responder
$58,333
Cost per Remission
$233,333
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov